PMC:7212965 / 37482-37729 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T178","span":{"begin":219,"end":227},"obj":"Disease"}],"attributes":[{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).\n\nAntimalarial Medications\nAlthough efficacy and subsequent optimal dosing in COVID-19 is still under inve"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T60","span":{"begin":12,"end":14},"obj":"Chemical"}],"attributes":[{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"}],"text":" Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).\n\nAntimalarial Medications\nAlthough efficacy and subsequent optimal dosing in COVID-19 is still under inve"}

{"project":"LitCovid-sentences","denotations":[{"id":"T233","span":{"begin":1,"end":141},"obj":"Sentence"},{"id":"T234","span":{"begin":143,"end":167},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).\n\nAntimalarial Medications\nAlthough efficacy and subsequent optimal dosing in COVID-19 is still under inve"}

{"project":"LitCovid-PubTator","denotations":[{"id":"934","span":{"begin":12,"end":14},"obj":"Gene"},{"id":"950","span":{"begin":219,"end":227},"obj":"Disease"}],"attributes":[{"id":"A934","pred":"tao:has_database_id","subj":"934","obj":"Gene:2770"},{"id":"A950","pred":"tao:has_database_id","subj":"950","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).\n\nAntimalarial Medications\nAlthough efficacy and subsequent optimal dosing in COVID-19 is still under inve"}